Clinical trial • Phase III • Psychiatry
Clinical trial in Major depressive disorder | Incomplete Response - Major Depressive Disorder (IR-MDD)
Phase III trial for Major depressive disorder | Incomplete Response - Major Depressive Disorder (IR-MDD). 72 participants.
Overview
- Trial Therapeutic Area
- Psychiatry
- Trial Disease
- Major depressive disorder | Incomplete Response - Major Depressive Disorder (IR-MDD)
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 22-08-2025
- First CTIS Authorization Date
- 31-10-2025
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 72
Eligibility
Recruits 72 No vulnerable populations selected; consent/assent handling not specified..
- Vulnerable Population
- No vulnerable populations selected; consent/assent handling not specified.
Recruitment
- Planned Sample Size
- 72
- Recruitment Window Months
- 9
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 72
Netherlands
- Earliest CTIS Part Ii Submission Date
- 22-10-2025
- Latest Decision Or Authorization Date
- 13-05-2026
- Processing Time Days
- 203
- Number Of Sites
- 1
- Number Of Participants
- 72
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Psychiatry
- Contact Person Name
- Gabriel Jacobs
- Contact Person Email
- clintrials@chdr.nl
Sponsor
Primary sponsor
- Full Name
- Otsuka Pharmaceutical Development & Commercialization Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Related trials
Other published trials that may interest you.